HIV-1 Envelope Overcomes NLRP3-Mediated Inhibition of F-Actin Polymerization for Viral Entry.

Actins / metabolism HIV-1 / metabolism Humans NLR Family, Pyrin Domain-Containing 3 Protein / metabolism Polymerization Signal Transduction Virus Internalization
CBL HIV NLRP3 P2Y2 inflammasome viral entry

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
24 09 2019
Historique:
received: 27 06 2018
revised: 08 01 2019
accepted: 22 02 2019
entrez: 26 9 2019
pubmed: 26 9 2019
medline: 21 10 2020
Statut: ppublish

Résumé

Purinergic receptors and nucleotide-binding domain leucine-rich repeat containing (NLR) proteins have been shown to control viral infection. Here, we show that the NLR family member NLRP3 and the purinergic receptor P2Y2 constitutively interact and regulate susceptibility to HIV-1 infection. We found that NLRP3 acts as an inhibitory factor of viral entry that represses F-actin remodeling. The binding of the HIV-1 envelope to its host cell receptors (CD4, CXCR4, and/or CCR5) overcomes this restriction by stimulating P2Y2. Once activated, P2Y2 enhances its interaction with NLRP3 and stimulates the recruitment of the E3 ubiquitin ligase CBL to NLRP3, ultimately leading to NLRP3 degradation. NLRP3 degradation is permissive for PYK2 phosphorylation (PYK2Y402

Identifiants

DOI: 10.1016/j.celrep.2019.02.095 PMID: 31553908
pubmed: 31553908
pii: S2211-1247(19)30281-5
doi: 10.1016/j.celrep.2019.02.095
pii:
doi:

Substances chimiques

Actins 0
NLR Family, Pyrin Domain-Containing 3 Protein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3381-3394.e7

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Audrey Paoletti (A)

Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Paris Sud - Paris 11, 114 rue Edouard Vaillant, F-94805 Villejuif, France.

Awatef Allouch (A)

Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Paris Sud - Paris 11, 114 rue Edouard Vaillant, F-94805 Villejuif, France.

Marina Caillet (M)

Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Paris Sud - Paris 11, 114 rue Edouard Vaillant, F-94805 Villejuif, France; INSERM U848, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France.

Hela Saïdi (H)

Institut Pasteur, Antiviral Immunity, Biotherapy and Vaccine Unit, Infection and Epidemiology Department, 25 rue du Dr. Roux, F-75015 Paris, France.

Frédéric Subra (F)

CNRS UMR 8113 LBPA, Ecole Normale Supérieure de Cachan, 61 avenue du Président Wilson, F-94230 Cachan, France.

Roberta Nardacci (R)

National Institute for Infectious Diseases "Lazzaro Spallanzani,", Via Portuense 292, 00149 Rome, Italy.

Qiuji Wu (Q)

Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Paris Sud - Paris 11, 114 rue Edouard Vaillant, F-94805 Villejuif, France.

Zeinaf Muradova (Z)

Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Paris Sud - Paris 11, 114 rue Edouard Vaillant, F-94805 Villejuif, France.

Laurent Voisin (L)

Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Paris Sud - Paris 11, 114 rue Edouard Vaillant, F-94805 Villejuif, France.

Syed Qasim Raza (SQ)

Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Paris Sud - Paris 11, 114 rue Edouard Vaillant, F-94805 Villejuif, France.

Frédéric Law (F)

Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Paris Sud - Paris 11, 114 rue Edouard Vaillant, F-94805 Villejuif, France.

Maxime Thoreau (M)

Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Paris Sud - Paris 11, 114 rue Edouard Vaillant, F-94805 Villejuif, France.

Haithem Dakhli (H)

Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Paris Sud - Paris 11, 114 rue Edouard Vaillant, F-94805 Villejuif, France.

Olivier Delelis (O)

CNRS UMR 8113 LBPA, Ecole Normale Supérieure de Cachan, 61 avenue du Président Wilson, F-94230 Cachan, France.

Béatrice Poirier-Beaudouin (B)

Institut Pasteur, Antiviral Immunity, Biotherapy and Vaccine Unit, Infection and Epidemiology Department, 25 rue du Dr. Roux, F-75015 Paris, France.

Nathalie Dereuddre-Bosquet (N)

INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Fontenay-aux-Roses, France; Université Paris Sud, UMR 1184, Fontenay-aux-Roses, France; CEA, DSV/iMETI, Division of Immunology-Virology, IDMIT, Fontenay-aux-Roses, France.

Roger Le Grand (R)

INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Fontenay-aux-Roses, France; Université Paris Sud, UMR 1184, Fontenay-aux-Roses, France; CEA, DSV/iMETI, Division of Immunology-Virology, IDMIT, Fontenay-aux-Roses, France.

Olivier Lambotte (O)

INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Fontenay-aux-Roses, France; CEA, DSV/iMETI, Division of Immunology-Virology, IDMIT, Fontenay-aux-Roses, France; APHP, Service de Médecine Interne - Immunologie Clinique, Hôpitaux Universitaires Paris Sud, F-94270 Le Kremlin-Bicêtre, France.

Asier Saez-Cirion (A)

Unité HIV, Inflammation et Persistance, Institut Pasteur, 25 rue du Dr. Roux, F-75025 Paris, France.

Gianfranco Pancino (G)

Unité HIV, Inflammation et Persistance, Institut Pasteur, 25 rue du Dr. Roux, F-75025 Paris, France.

David M Ojcius (DM)

Department of Biomedical Sciences, University of the Pacific, Arthur A. Dugoni School of Dentistry, 155 Fifth Street, San Francisco, CA 94103, USA; Université Paris Diderot, Sorbonne Paris Cité, 75013 Paris, France.

Eric Solary (E)

INSERM U1009, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France.

Eric Deutsch (E)

Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Paris Sud - Paris 11, 114 rue Edouard Vaillant, F-94805 Villejuif, France.

Mauro Piacentini (M)

National Institute for Infectious Diseases "Lazzaro Spallanzani,", Via Portuense 292, 00149 Rome, Italy; Department of Biology, University of Rome "Tor Vergata,", Via della Ricerca Scientifica 1, 00133 Rome, Italy.

Marie-Lise Gougeon (ML)

Institut Pasteur, Antiviral Immunity, Biotherapy and Vaccine Unit, Infection and Epidemiology Department, 25 rue du Dr. Roux, F-75015 Paris, France.

Guido Kroemer (G)

INSERM U848, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Metabolomics Platform, Gustave Roussy, 114 rue Edouard Vaillant, Villejuif, France; Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.

Jean-Luc Perfettini (JL)

Cell Death and Aging Team, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Laboratory of Molecular Radiotherapy, INSERM U1030, Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Gustave Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Université Paris Sud - Paris 11, 114 rue Edouard Vaillant, F-94805 Villejuif, France; Department of Biomedical Sciences, University of the Pacific, Arthur A. Dugoni School of Dentistry, 155 Fifth Street, San Francisco, CA 94103, USA. Electronic address: perfettini@orange.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du cytosquelette › Protéines des microfilaments › Actines › HIV-1 Envelope Overcomes NLRP3-Mediated...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › VIH-1 (Virus de l'Immunodéficience Humaine de type 1) › HIV-1 Envelope Overcomes NLRP3-Mediated...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › HIV-1 Envelope Overcomes NLRP3-Mediated...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Protéines NLR › Protéine-3 de la famille des NLR contenant un domaine pyrine › HIV-1 Envelope Overcomes NLRP3-Mediated...
questionsmedicales.fr › Phénomènes chimiques › Polymérisation › HIV-1 Envelope Overcomes NLRP3-Mediated...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › HIV-1 Envelope Overcomes NLRP3-Mediated...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Pénétration virale › HIV-1 Envelope Overcomes NLRP3-Mediated...